Patient Recruitment

Patient recruitment can delay your clinical trials and create cost overruns in medical device development. Processes designed with precision and approved efficiently still fail when investigators fail to identify, screen, and enrol subjects at projected rates. Slow recruitment extends trial timelines, increases monitoring costs, strains investigator relationships, and delays market entry.

Detailed study designs

Eligibility criteria determine who participates in your study. Overly broad criteria introduce inconsistencies that obscure treatment effects and invite confounding variables. Overly restrictive criteria slow recruitment to unusable rates (while limiting the generalisability of results).

Inclusion criteria need to define your population using objective, measurable parameters. Avoid subjective descriptors such as ‘moderate disease’ or ‘suitable anatomy.’ Instead, specify validated clinical scale scores, laboratory value ranges, imaging findings, or anatomical measurements. If your device targets coronary artery disease, specify minimum stenosis percentages, affected vessel requirements, and the symptom severity thresholds using standard definitions. Meanwhile, exclusion criteria require equal precision that avoid unnecessary restrictions. Include only exclusions that genuinely affect safety, complicate outcome assessment, or prevent proper device use. Each additional exclusion criterion reduces your eligible population and slows recruitment. Ask yourself whether every exclusion is necessary (or reflects excessive caution).

Pilot your criteria before full enrolment. Review medical records at proposed sites to estimate how many patients meet your criteria. Many founders discover their carefully designed criteria exclude 90% of potential participants to render recruitment targets impossible. Better to discover this during planning than after expensive site activation. Eligibility criteria for animal studies require similar precision. Using non-standard animal models invites regulatory questions while potentially compromising result relevance to human use.

Selecting sites for realistic recruitment

Site selection determines recruitment success more than any other factor. Founders often choose sites based on investigator reputation, institutional prestige, or geographic convenience, while ignoring whether sites actually see sufficient eligible patients. Make sure to assess site patient volumes through detailed feasibility questionnaires. Request specifics about how many patients with your target condition they treat monthly, what percentage meet your eligibility criteria, and what competing trials might claim the same population. Be sceptical of overly optimistic projections. Investigators routinely overestimate their eligible populations by factors of two to five.

The single biggest mistake in trial planning is accepting investigator recruitment estimates at face value. Sites consistently overestimate patient volumes because they think about total patients with the condition rather than the subset meeting specific eligibility criteria who aren't already enrolled in competing trials.

_{Professor Janet Peacock. Professor of Medical Statistics. King's College London}

Diversify your site portfolio. Relying on one or two high-volume centres creates vulnerability when those sites underperform. A network of medium-volume sites often outperforms a few prestigious institutions because medium-volume sites typically have fewer competing trials and more motivated investigators seeking to build research programmes. Consider practical logistics that affect your recruitment. Sites in urban centres with excellent public transport enrol more successfully than suburban sites requiring car ownership. Sites with weekend or evening clinic hours accommodate working patients better than those operating only during business hours.

For animal studies, vendor selection will require similar diligence. Verify that commercial vendors or institutional colonies can supply animals meeting your specifications within your timeline. Establish backup vendors to prevent delays if primary sources cannot deliver.

Maintaining ethics compliance

Institutional Review Board (IRB) or Institutional Animal Care and Use Committee (IACUC) approval represents the minimum ethics threshold. Maintaining compliance throughout recruitment and study conduct requires ongoing attention to consent processes, participant welfare, and regulatory reporting. Informed consent is more than form signing: It demands a genuine understanding verified through teach-back methods, where participants explain the study in their own words. Recruitment staff will need to be trained to present information clearly, answer questions honestly, and assess comprehension, rather than simply collecting signatures. Monitor consent comprehension through quality audits, review a sample of consent discussions through observation or recording. Assess whether staff rush through forms, adequately explain risks, or pressure participants toward enrolment (poor consent practices invite regulatory action that can halt trials, regardless of scientific merit).

Animal welfare monitoring requires equal vigilance. Implement humane endpoint protocols preventing unnecessary suffering. Train personnel to recognise distress signs that trigger early intervention or euthanasia. Document animal wellbeing throughout studies to demonstrate compliance with approved protocols.

Preventing dropout through engagement

Subject retention matters as much as recruitment. Studies powered for 100 evaluable subjects that lose 20% to dropout become underpowered, potentially failing to demonstrate real treatment benefits. This prevention begins during recruitment and continues through final follow-up. Aim to set realistic expectations during consent. Participants who understand time commitments, visit frequencies, and procedure requirements before enrolling are less likely to withdraw. Those recruited through overly optimistic descriptions of minimal burden often drop out when reality exceeds expectations.

Minimise participant burden through thoughtful protocol design. Offer flexible scheduling to accommodate work and family commitments. Provide transportation assistance or remote visit options when feasible. Compensate participants fairly for time and expenses without creating undue cost. Maintain regular communication with enrolled participants. Reminder calls before visits, thank you notes after completion, and periodic updates about study progress all reinforce engagement. Participants who feel valued and informed remain committed.

Founders celebrate hitting enrolment targets, then watch helplessly as 25% of subjects drop out before the primary endpoint assessment. Build retention strategies into protocols from the start. Budget for participant incentives, transportation assistance, and coordinator time maintaining engagement.

_{Dr. Deborah Ashby. Professor of Medical Statistics and Clinical Trials. Imperial College London}

For animal studies, maintaining stable populations requires careful husbandry, environmental enrichment, and health monitoring. Animals stressed by poor housing or inadequate veterinary care develop health problems that compromise your data quality or necessitate removal from studies.

Ensure data translates to real-world use

Study populations need to reflect the diversity of real-world device users. Trials enrolling only young, healthy males from academic medical centres generate results of questionable applicability to elderly women with other health conditions treated in community hospitals.

Plan diversity intentionally through site selection and recruitment strategies. Include sites serving diverse socioeconomic populations and geographic regions. Develop recruitment materials in multiple languages. Partner with community organisations that reach underserved populations. Train staff with culturally sensitive recruitment approaches. Monitor enrolment demographics continuously. If your population skews heavily toward one demographic group, investigate barriers that prevent broader recruitment. Transportation challenges, language barriers, cultural mistrust of research, or inflexible visit schedules all disproportionately affect certain populations. Include the full spectrum of disease severity, anatomical variations, and comorbidity profiles relevant to your target population. Real-world patients are complicated. Trials enrolling only ideal candidates generate results of limited applicability to clinical practice.

The recruitment workshop

The right learning can make all the difference between whether your trials are completed on schedule and within budget. We can help you design precise eligibility criteria that balance internal validity against recruitment feasibility. Select sites based on realistic patient volume assessments. Maintain rigorous ethics compliance throughout recruitment and follow-up. Prevent dropout through engagement strategies and burden minimisation. Ensure diverse cohorts reflecting real-world populations. Slow recruitment doesn't just delay trials. It can increase costs by 30% or more through extended monitoring (whilst postponing the commercial revenue that development investments require).

Waypoint checklist

Your path to patient recruitment should include the following:

• Precise criteria that avoid confounders in humans/animals
• Realistic sourcing that vets sites/vendors for timely enrolment
• Ethics first, where IRB/IACUC compliance is non-negotiable
• Prevent dropout to keep subjects/animals engaged/stable
• Ensure data translates to real-world use